Correlation of Platinum Cytotoxicity to Drug-DNA Adduct Levels in a Breast Cancer Cell Line Panel-Reference-Cited by-同舟云学术

Correlation of Platinum Cytotoxicity to Drug-DNA Adduct Levels in a Breast Cancer Cell Line Panel

Published:2018-11-01 Issue:12 Volume:31 Page:1293-1304
ISSN:0893-228X
Container-title:Chemical Research in Toxicology
language:en
Short-container-title:Chem. Res. Toxicol.

Author:

Wang Sisi¹,Scharadin Tiffany M.¹²,Zimmermann Maike¹²,Malfatti Michael A.³,Turteltaub Kenneth W.³,de Vere White Ralph³,Pan Chong-Xian¹⁴⁵,Henderson Paul T.¹²^ORCID

Affiliation:

1. Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis, Sacramento, California 95817, United States

2. Accelerated Medical Diagnostics Incorporated, Berkeley, California 95618, United States

3. Lawrence Livermore National Laboratory, Livermore, California 94550, United States

4. Department of Urology, University of California Davis Medical Center, Sacramento, California 95817, United States

5. VA Northern California Health Care System, Mather, California 95655, United States

Funder

National Cancer Institute

U.S. Department of Veterans Affairs

Susan and Gerry Knapp Family Fund

Publisher

American Chemical Society (ACS)

Subject

Toxicology,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.chemrestox.8b00170

Reference72 articles.

1. Society, A. C. (2017) Cancer Facts & Figures 2017, American Cancer Society, Atlanta, GA.

2. Adjuvant Trastuzumab in HER2-Positive Breast Cancer

3. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

4. Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer

5. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Unique Pt(II)-Induced Nucleolar Stress Response and its Deviation from DNA Damage Response Pathways;2024-06-07

2. DNA Adducts in Cancer Chemotherapy;Journal of Medicinal Chemistry;2024-03-29

3. Platinum-based chemotherapy: trends in organic nanodelivery systems;Nanoscale;2024

4. N6-Methyladenosine RNA Modifications Regulate the Response to Platinum Through Nicotinamide N-methyltransferase;Molecular Cancer Therapeutics;2023-01-09

5. Treatment of Triple Negative Cell Lines with Olaparib to Block DNA Repair;Anti-Cancer Agents in Medicinal Chemistry;2021-10-08